Faculty of Pharmacy and Pharmaceutical Sciences, University of Alberta, Edmonton, Alberta, Canada.
J Pharm Pharm Sci. 2011;14(3):387-99. doi: 10.18433/j37s36.
In Canada, asthma is the leading cause of admission in hospital. About of 80% of the death from asthma is preventable. Severe asthma is defined as a patient with persistent symptoms despite the use of adequate controller therapy, including multiple courses of oral glucocorticosteroids. However, about 10% of patients with severe asthma remain poorly controlled despite optimal treatment and these patients have the greatest morbidity and mortality. The management of refractory severe asthma remains extremely challenging. For patients with refractory severe asthma, the adjunct therapies recommended by national guidelines only included oral glucocorticosteroid and anti-IgE antibody (omalizumab) therapy. Currently, there is limited published literature on the unconventional treatments of refractory severe asthma. The objective of this review article is to provide an updated therapeutic overview of unconventional treatment options for refractory severe asthma.
在加拿大,哮喘是导致住院的主要原因。大约 80%的哮喘死亡是可以预防的。严重哮喘的定义是指尽管使用了足够的控制药物治疗,包括多次口服糖皮质激素治疗,但仍存在持续症状的患者。然而,大约 10%的严重哮喘患者尽管接受了最佳治疗仍控制不佳,这些患者的发病率和死亡率最高。难治性严重哮喘的治疗仍然极具挑战性。对于难治性严重哮喘患者,国家指南推荐的辅助治疗仅包括口服糖皮质激素和抗 IgE 抗体(奥马珠单抗)治疗。目前,关于难治性严重哮喘的非常规治疗方法的文献有限。本文的目的是为难治性严重哮喘的非常规治疗方法提供一个更新的治疗概述。